Cargando…

Riociguat: PATENT-1 Study

Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat...

Descripción completa

Detalles Bibliográficos
Autor principal: Said, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bloomsbury Qatar Foundation Journals 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220430/
https://www.ncbi.nlm.nih.gov/pubmed/25405174
http://dx.doi.org/10.5339/gcsp.2014.21
_version_ 1782342733609828352
author Said, Karim
author_facet Said, Karim
author_sort Said, Karim
collection PubMed
description Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat to treat pulmonary arterial hypertension in adults. Support for the approval of riociguat comes from the recently published PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1) study.
format Online
Article
Text
id pubmed-4220430
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bloomsbury Qatar Foundation Journals
record_format MEDLINE/PubMed
spelling pubmed-42204302014-11-17 Riociguat: PATENT-1 Study Said, Karim Glob Cardiol Sci Pract Lessons from the Trials Stimulators of soluble guanylate cyclase (sCG) are novel pharmacological agents that directly stimulate sGC. Ongoing research on sGC stimulators led to the development of the more potent and more specific sGC stimulator, riociguat. Recently, the US Food and Drug Administration has approved riociguat to treat pulmonary arterial hypertension in adults. Support for the approval of riociguat comes from the recently published PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1) study. Bloomsbury Qatar Foundation Journals 2014-06-18 /pmc/articles/PMC4220430/ /pubmed/25405174 http://dx.doi.org/10.5339/gcsp.2014.21 Text en © 2014 Said, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Lessons from the Trials
Said, Karim
Riociguat: PATENT-1 Study
title Riociguat: PATENT-1 Study
title_full Riociguat: PATENT-1 Study
title_fullStr Riociguat: PATENT-1 Study
title_full_unstemmed Riociguat: PATENT-1 Study
title_short Riociguat: PATENT-1 Study
title_sort riociguat: patent-1 study
topic Lessons from the Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220430/
https://www.ncbi.nlm.nih.gov/pubmed/25405174
http://dx.doi.org/10.5339/gcsp.2014.21
work_keys_str_mv AT saidkarim riociguatpatent1study